Bivalirudin

Generic Name: Bivalirudin

Brand Names: Angiomax

Drug Type: Small Molecule

Chemical Formula: C_₉₈H_₁₃₈N_₂₄O_₃₃

CAS Number: 128270-60-0

Unique Ingredient Identifier: TN9BEX005G

Background: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

Indication: For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.

Associated Conditions: Thrombosis

Associated Therapies: -

Clinical Trials

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Device: Bare metal stent
Drug: Bivalirudin
Device: Paclitaxel-eluting stent
Drug: Unfractionated heparin

First Posted Date: 2007-02-12

Last Posted Date: 2017-12-04

Lead Sponsor: Cardiovascular Research Foundation, New York

Target Recruit Count: 3602

Registration Number: NCT00433966

Locations: 🇺🇸
LeBauer CV Research Foundation, Greensboro, North Carolina, United States

Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome

Phase 4

Completed

Conditions: Coronary Disease
Myocardial Infarction

Interventions: Drug: Abciximab + UFH
Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2006-09-08

Last Posted Date: 2012-05-08

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 1721

Registration Number: NCT00373451

Locations: 🇩🇪
Medizinische Klinik, Klinikum rechts der Isar, Muenchen, Germany
🇩🇪
Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
🇩🇪
Herz- und Gefaessklinik, Kardiologie, Bad Neustadt, Germany

and more 6 locations

ImproveR International (BI-001-IM)

Completed

Conditions: Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

First Posted Date: 2006-02-13

Last Posted Date: 2012-05-07

Lead Sponsor: Nycomed

Target Recruit Count: 4000

Registration Number: NCT00290849

Locations: 🇩🇰
Nycomed, Roskilde, Denmark

Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)

Phase 4

Completed

Conditions: Coronary Disease
Angina Pectoris

Interventions: Drug: Un-fractionated heparin
Drug: Bivalirudin

First Posted Date: 2005-12-06

Last Posted Date: 2010-03-15

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 4570

Registration Number: NCT00262054

Locations: 🇩🇪
First Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
🇩🇪
Herz-Zentrum, Bad Krozingen, Germany
🇩🇪
Segeberger Kliniken, Bad Segeberg, Germany

and more 1 locations